glp-1 weight watchers program WeightWatchers Introduces Groundbreaking Loss Weight Watchers GLP-1 Med+ Review

Los estudios de resultados cardiovasculares han demostrado que ciertos agonistas GLP-1 (como liraglutida, semaglutida y dulaglutida) reducen significativamente el riesgo de eventos cardiovasculares mayores (infarto de miocardio, accidente cerebrovascular y muerte cardiovascular) en pacientes con diabetes tipo 2 y enfermedad cardiovascular establecida o mltiples factores de riesgo

The Antioxidant Edge: Measuring and Protecting Your Brains Resilience Against Ageing (Originally posted in IHCAN magazine

J Pharmacol Exp Ther 206(1):227232 Di Stefano A, Sozio P, Cerasa LS (2008) Antiparkinson prodrugs

Have a BMI of 27 or higher, plus a weight-related condition like high blood pressure, sleep apnea, or Type 2 diabetes In recent years, the FDA has expanded approvals, like approving Zepbound for weight management in 2023 and a generic liraglutide (the active ingredient in Saxenda and Victoza) in 2025